Orakl Oncology

✈️ Orakl Oncology at ESMO 2025 (Berlin, October 17–21)! At this year’s ESMO - European Society for Medical Oncology Congress, Orakl Oncology will present two posters highlighting how the combination of AI and patient-derived biology is transforming the way we predict the efficacy of new treatments in oncology — even before the first patient is dosed. 📍Poster 78eP “Patient-derived organoids reveal heterogeneous response to KRAS inhibition in digestive tumors.” ➡️ This study shows how patient-derived organoids explain why some digestive cancers respond — and others resist — to KRAS inhibitor drug candidates (which target mutations present in ~90% of pancreatic and ~40% of colorectal cancers). Presented by Jérôme Caron, PhD, Head of Laboratory at Orakl Oncology. 📍Poster 6P “Patient-derived organoid assays and AI modeling predict clinical trial outcomes in colorectal cancer.” ➡️ This work demonstrates how AI-powered patient avatars can forecast clinical trial results — addressing one of oncology’s toughest realities: only 5% of drug candidates that enter trials ultimately reach patients. Presented by Gustave Ronteix, CTO, with contributions from Jean Bouteiller, Head of Data Science. Our leadership team — Fanny Jaulin, PhD (CEO), Diane-Laure Pagès (COO), Benjamin Shore (Head of BD), Mathieu Raul (Head of Partnerships), and Thibaud Caspari (Chief of Staff) — will also be attending 🤝 We’d love to connect — come meet us in Berlin or reach out during the congress!

🏆 Thanks to the Norrsken evaluation committee for selecting Orakl Oncology as one of their 100 impact startups... and take us to NYC! 🌆 It’s a special return for me — back to my favorite city in the world, where I was first introduced to cancer cell biology and 3D organotypic cultures during my time at Memorial Sloan Kettering Cancer Center and Weill Cornell Graduate School of Medical Sciences. 🧫 Now, I’m coming back with Orakl, on a mission to reinvent how drugs are developed — to bring many more effective medicines to cancer patients. ✨ Excited for what’s ahead, and grateful to the Norrsken team for highlighting our commitment to positively impact society!

🌍 We made it to Times Square! ✨ Out of 1300+ impact companies nominated worldwide, Orakl Oncology has been selected for this year’s Norrsken Impact/100 — highlighting the world’s most promising startups driving positive change. The selection was made together with leading investors including Sequoia Capital, Breakthrough Energy , Atomico, Andreessen Horowitz, Khosla Ventures, DC/VC, and others. Being featured on the Times Square billboard is a powerful moment — a symbol of how far we’ve come and how far we can go. With an ecosystem of talented teams, strong hospital and pharma partners, committed investors,  Orakl Oncology can dream big and work to make cancer a chronic disease through the power of AI and biology. 💡 A huge thank you to the Norrsken VC Foundation, and to everyone who contributes to this mission every day. 🙌

🌍 We made it to Times Square! ✨ Out of 1300+ impact companies nominated worldwide, Orakl Oncology has been selected for this year’s Norrsken Impact/100 — highlighting the world’s most promising startups driving positive change. The selection was made together with leading investors including Sequoia Capital, Breakthrough Energy , Atomico, Andreessen Horowitz, Khosla Ventures, DC/VC, and others. Being featured on the Times Square billboard is a powerful moment — a symbol of how far we’ve come and how far we can go. With an ecosystem of talented teams, strong hospital and pharma partners, committed investors,  Orakl Oncology can dream big and work to make cancer a chronic disease through the power of AI and biology. 💡 A huge thank you to the Norrsken VC Foundation, and to everyone who contributes to this mission every day. 🙌

More than 95% of oncology drug candidates fail in clinical trials. This considerably slows down the development of successful treatments for patients since researchers spend time and focus on unsuccessful programs. But improving the quality of decision-making is also smart financial maths (see the figure that I borrowed from Andreas Bender's great 2021 paper, link in the comments). Even marginal improvements in clinical trial success rates can have enormous impact on the overall drug program finances. Ultimately, this problem boils down to the lack of high-quality data and models to guide decision makers when they are facing key decisions around their therapeutic program. But predicting how a drug will work in a patient with the current tools at the disposal of researchers is tough: today's clinical trial success rates are a testament to that. We're working on changing the status quo with Orakl Oncology. By pairing experiments with drug candidates on patient avatars, coupled with the suite of models we have developed, we can get best in class predictions of trial outcomes in PDAC and CRC, for chemotherapies, targeted therapies and combinations thereof. Specifically, we show that we predict the success of RMC6236 against folfirinox in 2nd line PDAC with G12X mutations, as was first reported last December. More generally, we predict the best treatment arm in more than 80% of cases. This is just the start though, and our next series of improvements will help us push the limits of clinical trial success. We'll be showcasing this data at #ESMO2025 in Berlin with Jérôme Caron and the rest of the team (Poster "6P - Patient-derived organoid assays and AI modeling predict clinical trial outcomes in colorectal cancer"). Come and ask me questions, drop me a DM if you want to know more ! Fanny Jaulin, PhD Diane-Laure Pagès Benjamin Shore Marc Robert de Massy

🚀 Orakl joins the 3rd edition of the Amazon Web Services (AWS) Generative AI Accelerator! We’re excited to announce that Orakl Oncology has been selected from over 2,000 startups worldwide to join the third cohort of the AWS Generative AI Accelerator — a global program by Amazon Web Services (AWS) that supports the most promising early-stage companies building the future of AI. Through this program, we’ll have access to AWS credits, expert mentorship, and advanced technical resources to strengthen our AI capabilities and scale our infrastructure — delivering unique insights to transform oncology drug developments, and ultimately bring more medicines to patients. Our CTO & Co-Founder Gustave Ronteix and Head of Data Jean Bouteiller are heading to Seattle 🇺🇸 to kick off the program and present our work to investors, partners, customers, and AWS leaders. A big thank you to AWS for this recognition and for championing the next generation of AI innovators. 👉 Learn more about the AWS Generative AI Accelerator: https://lnkd.in/eB2_zyxG

Odyssea 2025 – Running Together to Fight Breast Cancer! 🎀 The Orakl Oncology and Gustave Roussy teams joined forces — with the invaluable support of the sun 🌞 — to take part in this year’s Odyssea race! This edition broke all records: 50,000 participants and €1,050,000 raised to support breast cancer research at Gustave Roussy. A heartfelt thank you to everyone who ran, donated, and supported this cause. Together, we’re moving research forward! 💪 Mia Cabantous Rafał Pietrzak Jérôme Caron Diane-Laure Pagès Emilie Gontran Florent Peglion, PhD Gustave Roussy Odysséa Organisation RHU ORGANOMIC

Our CEO, Fanny Jaulin, PhD, was interviewed by Estelle Botbol 🎗️ from Speedinvest for the second edition of the Founder Coffee Chat. She shared how Orakl Oncology was born from her journey as a cancer researcher and her ambition to develop transformative drugs to treat many more patients. Transitioning from academia to start-ups and deploy innovation to significantly impact society requires investors who believe in scientific founders! At Orakl Oncology, we are proud to build our future in close collaboration with our investors — our long-time believers: Speedinvest, HCVC, and Verve Ventures, as well as our new partners Singular and SISTAFUND. Their diverse backgrounds shed new lights and interesting perspectives, helping us co-create Orakl Oncology trajectory and drive our mission forward. Jeremy Uzan Andrea Zitna Xavier Mesnier Alexis Houssou Tatiana Jama

This week the Orakl Oncology team is heading to #ESGMOGI in Barcelona. We’re seizing this opportunity to present new data demonstrating how patient avatars and Orakl Oncology’s proprietary AI stack to anticipate clinical trial outcomes in GI cancers. Come and meet Jean Bouteiller and Gustave Ronteix at our poster. Interested in knowing more about Orakl Oncology? Our CEO Fanny Jaulin, PhD and our COO Diane-Laure Pagès will be there to explain how we can help you accelerate and derisk your clinical development efforts. You’re a hospital or a clinician and you’re interested in working with us ? Our Head of Partnerships Mathieu Raul will also be there to meet with the medical community. 🧬 Join us at poster 502P on Thursday morning. 👉 This work has been conducted thanks to the support of the RHU ORGANOMIC and Gustave Roussy. Fanny Jaulin, PhD, Diane-Laure Pagès, Gustave Ronteix, Mathieu Raul, Jean Bouteiller